Sbg Lifesciences Limited

Sbg Lifesciences Limited, based in London, UK, is a small, active company founded eight years ago. With just two employees and £45,568 in assets, it operates from a virtual address shared by over a hundred other companies, raising questions about its physical presence. The company has two directors and one owner, with Thomas Bianchi at the helm. It functions as an irregular importer, primarily dealing in miscellaneous chemical products, with the last import operation occurring over two years ago.

The company’s website highlights its role as a London-based consultancy firm specializing in the Medtech and Biotech sectors, both in Europe and beyond. It offers services like market research, advisory board management, and strategic business planning, targeting startup and SME clients. Sbg Lifesciences Ltd emphasizes a partnership approach, leveraging the expertise of Managing Director Thomas Bianchi, who also advises several SMEs and is a partner at RegeneXB, a biotechnology startup. The website details Bianchi’s extensive experience in the industry, including roles at Medtronic, Stryker, and Covidien.

Financially, Sbg Lifesciences Limited is showing some concerning trends. Current assets have decreased by 14% to £46,000, and net assets have plummeted 37% to £14,000. Cash reserves have also declined significantly, dropping 24% to £11,000. While creditors have decreased slightly, the sharp decline in equity suggests the company is burning through cash. The company’s small size (meeting two of three criteria for a small company) allows for agility, but the financial pressures are evident. The unaudited financial statements, overseen by TC Group, don’t offer a full picture of the company’s health, and the lack of detailed information makes it difficult to assess its long-term viability.

Registered in England/Wales under the registration number 10765447, with a registered address at SW1Y 4BP, United Kingdom, London, Tc Group 6th Floor Kings House, 9 - 10 Haymarket.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.